Wermke, M., Araujo, D. M., Chatterjee, M., Tsimberidou, A. M., Holderried, T. A. W., Jazaeri, A. A., Reshef, R., Bokemeyer, C., Alsdorf, W., Wetzko, K., Brossart, P., Aslan, K., Backert, L., Bunk, S., Fritsche, J., Gulde, S., Hengler, S., Hilf, N., Hossain, M. B., … Britten, C. M. (2025). Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-025-03650-6

Vasou, A., Nightingale, K., Cetkovská, V., Scheler, J., Bamford, C. G. G., Andrejeva, J., Rowe, J. C., Swatek, K. N., Schwarz‐Linek, U., Randall, R. E., McLauchlan, J., Weekes, M. P., Bogunovic, D., & Hughes, D. J. (2025). ISG15‐Dependent Stabilisation of USP18 Is Necessary but Not Sufficient to Regulate Type I Interferon Signalling in Humans. European Journal of Immunology, 55(2). Portico. https://doi.org/10.1002/eji.202451651

Yoon, A. J., Carvajal, R. D., Graboyes, E. M., Kaczmar, J. M., Albergotti, W. G., Kejner, A. E., Troob, S. H., Philipone, E., Anoma, J.-S., Armeson, K. E., Hill, E. G., Richardson, M. S., Woods, T. R., Chera, B. S., Nourollah-Zadeh, F., Lee, B. J., Pandruvada, S., Kourtidis, A., Kingsley, C., … Newman, J. G. (2025). Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1530262

Lopez, J., Powles, T., Braiteh, F., Siu, L. L., LoRusso, P., Friedman, C. F., Balmanoukian, A. S., Gordon, M., Yachnin, J., Rottey, S., Karydis, I., Fisher, G. A., Schmidt, M., Schuler, M., Sullivan, R. J., Burris, H. A., Galvao, V., Henick, B. S., Dirix, L., … Camidge, D. R. (2025). Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature Medicine, 31(1), 152–164. https://doi.org/10.1038/s41591-024-03334-7

Stein, M. N., Dumbrava, E. E., Teply, B. A., Gergis, U. S., Guiterrez, M. E., Reshef, R., Subudhi, S. K., Jacquemont, C. F., Senesac, J. H., Bayle, J. H., Scripture, C. D., Chatwal, M. S., Bilen, M. A., Stadler, W. M., & Becerra, C. R. (2024). PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-53220-6

Dimitriou, F., Orloff, M. M., Koch Hein, E. C., Cheng, P. F., Hughes, I. F., Simeone, E., Montazeri, K., Grover, P., Mehmi, I., Gerard, C. L., Gaudy-Marqueste, C., Grob, J.-J., Michielin, O., Hamid, O., Long, G. V., Sullivan, R., Kapiteijn, E., Johnson, D. B., Ascierto, P. A., … Dummer, R. (2025). Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. European Journal of Cancer, 214, 115161. https://doi.org/10.1016/j.ejca.2024.115161

Hertel, A., Aguiar, T., Mashiko, S., Núñez, S., Moore, C., Gao, B., Ausmeier, M., Roy, P., & Zorn, E. (2024). Clones reactive to apoptotic cells and specific chemical adducts are prevalent among human thymic B cells. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1462126

Li, F., Yang, Z., Savage, T. M., Vincent, R. L., de los Santos-Alexis, K., Ahn, A., Rouanne, M., Mariuzza, D. L., Danino, T., & Arpaia, N. (2024). Programmable bacteria synergize with PD-1 blockade to overcome cancer cell–intrinsic immune resistance mechanisms. Science Immunology, 9(100). https://doi.org/10.1126/sciimmunol.adn9879

Redenti, A., Im, J., Redenti, B., Li, F., Rouanne, M., Sheng, Z., Sun, W., Gurbatri, C. R., Huang, S., Komaranchath, M., Jang, Y., Hahn, J., Ballister, E. R., Vincent, R. L., Vardoshivilli, A., Danino, T., & Arpaia, N. (2024). Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature, 635(8038), 453–461. https://doi.org/10.1038/s41586-024-08033-4

Hao, L. Y., Lerrer, S., Paiola, M., Moore, E. K., Gartshteyn, Y., Song, R., Goeckeritz, M., Black, M. J., Bukhari, S., Hu, X., & Mor, A. (2024). Exclusion of PD-1 from the immune synapse: A novel strategy to modulate T cell function. Molecular Therapy: Oncology, 32(3), 200839. https://doi.org/10.1016/j.omton.2024.200839

Zhong, J., Lerrer, S., & Mor, A. (2024). An Imaging-Based Assay to Measure the Location of PD-1 at the Immune Synapse for Testing the Binding Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies. BIO-PROTOCOL, 14(1352). https://doi.org/10.21769/bioprotoc.5057

Latzer, P., Zelba, H., Battke, F., Reinhardt, A., Shao, B., Bartsch, O., Rabsteyn, A., Harter, J., Schulze, M., Okech, T., Golf, A., Kyzirakos-Feger, C., Kayser, S., Pieper, N., Feldhahn, M., Wünsche, J., Seitz, C., Hadaschik, D., Garbe, C., … Biskup, S. (2024). A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-51315-8

Gray, J. I., Caron, D. P., Wells, S. B., Guyer, R., Szabo, P., Rainbow, D., Ergen, C., Rybkina, K., Bradley, M. C., Matsumoto, R., Pethe, K., Kubota, M., Teichmann, S., Jones, J., Yosef, N., Atkinson, M., Brusko, M., Brusko, T. M., Connors, T. J., … Farber, D. L. (2024). Human γδ T cells in diverse tissues exhibit site-specific maturation dynamics across the life span. Science Immunology, 9(96). https://doi.org/10.1126/sciimmunol.adn3954

Nanaware, P. P., Khan, Z. N., Clement, C. C., Shetty, M., Mota, I., Seltzer, E. S., Dzieciatkowska, M., Gamboni, F., D’Alessandro, A., Ng, C., Nagayama, M., Lichti, C. F., Soni, R. K., Jacob B. Geri, Matei, I., Lyden, D., Longman, R., Lu, T. T., Wan, X., … Santambrogio, L. (2024). Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load. Cell Reports, 43(6), 114311. https://doi.org/10.1016/j.celrep.2024.114311

Loffredo, L. F., Savage, T. M., Ringham, O. R., & Arpaia, N. (2024). Treg–tissue cell interactions in repair and regeneration. Journal of Experimental Medicine, 221(6). https://doi.org/10.1084/jem.20231244

O’Shea, J., Zucker, J., Stampfer, S., Cash-Goldwasser, S., Minhaj, F. S., Dretler, A., Cheeley, J., Chaudhuri, S., Gallitano, S. M., Gunaratne, S., Parkinson, M., Epling, B., Morcock, D. R., Sereti, I., & Deleage, C. (2023). Prolonged Mpox Disease in People With Advanced HIV: Characterization of Mpox Skin Lesions. The Journal of Infectious Diseases, 229(Supplement_2), S243–S248. https://doi.org/10.1093/infdis/jiad532

Philips, E. A., Liu, J., Kvalvaag, A., Mørch, A. M., Tocheva, A. S., Ng, C., Liang, H., Ahearn, I. M., Pan, R., Luo, C. C., Leithner, A., Qin, Z., Zhou, Y., Garcia-España, A., Mor, A., Littman, D. R., Dustin, M. L., Wang, J., & Kong, X.-P. (2024). Transmembrane domain–driven PD-1 dimers mediate T cell inhibition. Science Immunology, 9(93). https://doi.org/10.1126/sciimmunol.ade6256

Zorko, N. A., Makovec, A., Elliott, A., Kellen, S., Lozada, J. R., Arafa, A. T., Felices, M., Shackelford, M., Barata, P., Zakharia, Y., Narayan, V., Stein, M. N., Zarrabi, K. K., Patniak, A., Bilen, M. A., Radovich, M., Sledge, G., El-Deiry, W. S., Heath, E. I., … Antonarakis, E. S. (2024). Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00797-0

Hilton, J. F., Ott, P. A., Hansen, A. R., Li, Z., Mathew, M., Messina, C. H., Dave, V., Ji, X., Karpinich, N. O., Hirschfeld, S., Ballas, M., & Zandberg, D. P. (2024). INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 73(3). https://doi.org/10.1007/s00262-023-03623-z

Miner, M. D., deCamp, A., Grunenberg, N., De Rosa, S. C., Fiore-Gartland, A., Bar, K., Spearman, P., Allen, M., Yu, P.-C., Manso, B., Frahm, N., Kalams, S., Baden, L., Keefer, M. C., Scott, H. M., Novak, R., Van Tieu, H., Tomaras, G. D., Kublin, J. G., … Luke-Kilolam, A. (2024). Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial. EBioMedicine, 100, 104987. https://doi.org/10.1016/j.ebiom.2024.104987

Fahmy, L. M., Schreidah, C. M., McDonnell, D. E., Carvajal, R. D., Magro, C. M., & Geskin, L. J. (2024). Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma. Dermatology Online Journal, 29(6). https://doi.org/10.5070/d329662993

Ko, B., Tao, K., Brennan, L., Rakhade, S., Chan, C. X., Moone, J.-Y., Zhu, R., Sher, A., Wang, S., Bracero, Y., Fullerton, B., McLellan, B., Geskin, L. J., & Saenger, Y. M. (2024). Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients. Melanoma Research, 34(2), 134–141. https://doi.org/10.1097/cmr.0000000000000945

Silva Souza, M., Pires Farias, J., Barros Luiz, W., Birbrair, A., Durães-Carvalho, R., de Souza Ferreira, L. C., & Amorim, J. H. (2023). Immune targets to stop future SARS-CoV-2 variants. Microbiology Spectrum, 11(6). https://doi.org/10.1128/spectrum.02892-23

Hawley, J. E., Obradovic, A. Z., Dallos, M. C., Lim, E. A., Runcie, K., Ager, C. R., McKiernan, J., Anderson, C. B., Decastro, G. J., Weintraub, J., Virk, R., Lowy, I., Hu, J., Chaimowitz, M. G., Guo, X. V., Zhang, Y., Haffner, M. C., Worley, J., Stein, M. N., … Drake, C. G. (2023). Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell, 41(11), 1972-1988.e5. https://doi.org/10.1016/j.ccell.2023.10.006

Daugherty, B. L., Boohaker, R. J., Johnstone, R., Stinson, K., Zhao, G., Zang, M., Qian, J., Wang, T. C., & Lederman, S. (2023). 1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.1345

Migden, M. R., Chai-Ho, W., Daniels, G. A., Wise-Draper, T. M., Kheterpal, M., Tang, J. C., Bolotin, D., Verschraegen, C., Poklepovic, A. S., Khan, S. A., Ibrahim, S. F., Zeitouni, N. C., Medina, T., Tsai, K. K., Tucci, C., Navia, S., Donthireddy, L., Bommareddy, P. K., Hou, J. W., & Davar, D. (2023). 777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS). Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0777

Ventin, M., Cattaneo, G., Jia, J., Arya, S., Maggs, L., Sun, Y., Boland, G. M., Jenkins, R. W., Ksander, B. R., Haq, R., Wang, X., Ryeom, S., Ferrone, C. R., & Ferrone, S. (2023). 317 B7-H3-targeted CAR T cell with an inducible caspase 9 suicide gene effectively eradicates uveal melanoma liver metastases. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0317

Sellyei, J., Yan, X., Qiu, W., Vasilescu, E., & Vlad, G. (2023). A novel HLA‐B*58:141 allele identified by next‐generation sequencing in a potential hematopoietic cell recipient. HLA, 103(1). Portico. https://doi.org/10.1111/tan.15237

Wei, A. Z., Chen, L. N., Orloff, M., Ariyan, C. E., Asgari, M., Barker, C. A., Buchbinder, E., Chandra, S., Couts, K., Frumovitz, M. M., Futreal, A., Gershenwald, J. E., Hanna, E. Y., Izar, B., LeBlanc, A. K., Leitao, M. M., Lipson, E. J., Liu, D., McCarter, M., … Carvajal, R. D. (2023). Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA). Pigment Cell & Melanoma Research, 36(6), 542–556. Portico. https://doi.org/10.1111/pcmr.13139

Orloff, M., Watkins, C., Carvajal, R. D., Shoushtari, A. N., Sacco, J. J., Schlaak, M., Gama, J., & Butler, M. O. (2023). 1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up. Annals of Oncology, 34, S678. https://doi.org/10.1016/j.annonc.2023.09.2263

Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., Luke, J. J., Mitchell, T. C., Mooradian, M. J., Rubin, K. M., Salama, A. K., Shirai, K., Taube, J. M., Tawbi, H. A., Tolley, J. K., … Sullivan, R. J. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for ImmunoTherapy of Cancer, 11(10), e006947. https://doi.org/10.1136/jitc-2023-006947

Ager, C. R., Zhang, M., Chaimowitz, M., Bansal, S., Tagore, S., Obradovic, A., Jugler, C., Rogava, M., Melms, J. C., McCann, P., Spina, C., Drake, C. G., Dallos, M. C., & Izar, B. (2023). KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. Journal for ImmunoTherapy of Cancer, 11(9), e006782. https://doi.org/10.1136/jitc-2023-006782

Ho, P., Melms, J. C., Rogava, M., Frangieh, C. J., Poźniak, J., Shah, S. B., Walsh, Z., Kyrysyuk, O., Amin, A. D., Caprio, L., Fullerton, B. T., Soni, R. K., Ager, C. R., Biermann, J., Wang, Y., Khosravi-Maharlooei, M., Zanetti, G., Mu, M., Fatima, H., … Izar, B. (2023). The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell, 41(7), 1207-1221.e12. https://doi.org/10.1016/j.ccell.2023.05.014

Heidarian, M., Jensen, I. J., Kannan, S. K., Pewe, L. L., Hassert, M., Park, S., Xue, H.-H., Harty, J. T., & Badovinac, V. P. (2023). Sublethal whole-body irradiation induces permanent loss and dysfunction in pathogen-specific circulating memory CD8 T cell populations. Proceedings of the National Academy of Sciences, 120(27). https://doi.org/10.1073/pnas.2302785120

Long, J., Soni, M., Muranski, P., Miller, M. J., Conry-Cantilena, C., & De Giorgi, V. (2023). Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1207638

Bullock, A., Fakih, M., Gordon, M., Tsimberidou, A., El-Khoueiry, A., Wilky, B., Pimentel, A., Margolin, K., Mahadevan, D., Balmanoukian, A., Sanborn, R., Schwartz, G., Abou-Alfa, G., Bockorny, B., Moser, J., Sharma, S., Grossman, J., Rosenthal, K., O’Day, S., … Schlechter, B. (2023). LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). Annals of Oncology, 34, S178–S179. https://doi.org/10.1016/j.annonc.2023.04.014

Tshering, L. F., Luo, F., Russ, S., Szenk, M., Rubel, D., Tutuska, K., Rail, J. G., Balázsi, G., Shen, M. M., & Talos, F. (2023). Immune mechanisms shape the clonal landscape during early progression of prostate cancer. Developmental Cell, 58(12), 1071-1086.e8. https://doi.org/10.1016/j.devcel.2023.04.010

Ahmed, M. S. U., Lord, B. D., Adu Addai, B., Singhal, S. K., Gardner, K., Salam, A. B., Ghebremedhin, A., White, J., Mahmud, I., Martini, R., Bedi, D., Lin, H., Jones, J. D., Karanam, B., Dean-Colomb, W., Grizzle, W., Wang, H., Davis, M., & Yates, C. C. (2023). Immune Profile of Exosomes in African American Breast Cancer Patients Is Mediated by Kaiso/THBS1/CD47 Signaling. Cancers, 15(8), 2282. https://doi.org/10.3390/cancers15082282

Ambrosini, G., Natale, C. A., Musi, E., Garyantes, T., & Schwartz, G. K. (2023). The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells. Cancer Research Communications, 3(4), 540–547. https://doi.org/10.1158/2767-9764.crc-22-0399

Orlow, I., Sadeghi, K. D., Edmiston, S. N., Kenney, J. M., Lezcano, C., Wilmott, J. S., Cust, A. E., Scolyer, R. A., Mann, G. J., Lee, T. K., Burke, H., Jakrot, V., Shang, P., Ferguson, P. M., Boyce, T. W., Ko, J. S., Ngo, P., Funchain, P., … Rees, J. R. (2023). InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PLOS ONE, 18(4), e0269324. https://doi.org/10.1371/journal.pone.0269324

Hamid, O., Lewis, K., Weise, A., McKean, M., Papadopoulos, K. P., Crown, J., Kim, T. M., Lakhani, N. J., Kaczmar, J., Kudchadkar, R., Spira, A., Rabinowits, G., Kim, K., Carvajal, R., Williamson, S., Ioffe, E., Chen, S., Mani, J., Jankovic, V., … Gullo, G. (2023). Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. SKIN The Journal of Cutaneous Medicine, 7(2), s179. https://doi.org/10.25251/skin.7.supp.179

Siddiqui, B. A., Chapin, B. F., Jindal, S., Duan, F., Basu, S., Yadav, S. S., Gu, A.-D., Espejo, A. B., Kinder, M., Pettaway, C. A., Ward, J. F., Tidwell, R. S. S., Troncoso, P., Corn, P. G., Logothetis, C. J., Knoblauch, R., Hutnick, N., Gottardis, M., Drake, C. G., … Subudhi, S. K. (2023). Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Journal for ImmunoTherapy of Cancer, 11(3), e006262. https://doi.org/10.1136/jitc-2022-006262

Kim, H. S., Ho, T.-C., Willner, M. J., Becker, M. W., Kim, H.-W., & Leong, K. W. (2023). Dendritic cell-mimicking scaffolds for ex vivo T cell expansion. Bioactive Materials, 21, 241–252. https://doi.org/10.1016/j.bioactmat.2022.08.015

Obradovic, A. (2023). Precision immunotherapy. Science, 379(6633), 654–655. https://doi.org/10.1126/science.adg5585

Poon, M. M. L., Caron, D. P., Wang, Z., Wells, S. B., Chen, D., Meng, W., Szabo, P. A., Lam, N., Kubota, M., Matsumoto, R., Rahman, A., Luning Prak, E. T., Shen, Y., Sims, P. A., & Farber, D. L. (2023). Tissue adaptation and clonal segregation of human memory T cells in barrier sites. Nature Immunology, 24(2), 309–319. https://doi.org/10.1038/s41590-022-01395-9

Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., Salacz, M. E., D’Andre, S., Aiken, R. D., Moshel, Y. A., Nam, J. Y., Pillainayagam, C. P., Wagner, S. A., Walter, K. A., Chaudhary, R., … Bosch, M. L. (2023). Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. JAMA Oncology, 9(1), 112. https://doi.org/10.1001/jamaoncol.2022.5370

Phares, T. W., Huang, J., Kotraiah, V., Hauser, M. J., Domi, A., Oruganti, S., Browne, C. D., Buontempo, P., Mansour, M., Pannucci, J., Tsuji, M., & Gutierrez, G. M. (2022). Viral delivery of a peptide-based immunomodulator enhances T cell priming during vaccination. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1029636

Anandakumaran, P. N., Ayers, A. G., Muranski, P., Creusot, R. J., & Sia, S. K. (2022). Rapid video-based deep learning of cognate versus non-cognate T cell-dendritic cell interactions. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-021-04286-5

Ascierto, P. A., Agarwala, S. S., Blank, C., Caracò, C., Carvajal, R. D., Ernstoff, M. S., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., Grob, J.-J., Hamid, O., Krogsgaard, M., Lo, R. S., Lund, A. W., Madonna, G., Michielin, O., Neyns, B., Osman, I., … Thurin, M. (2022). Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy). Journal of Translational Medicine, 20(1). https://doi.org/10.1186/s12967-022-03592-4

Hagan, T., Gerritsen, B., Tomalin, L. E., Fourati, S., Mulè, M. P., Chawla, D. G., Rychkov, D., Henrich, E., Miller, H. E. R., Diray-Arce, J., Dunn, P., Lee, A., Deckhut-Augustine, A., Gottardo, R., Haddad, E. K., Hafler, D. A., Harris, E., Farber, D., … Pulendran, B. (2022). Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses. Nature Immunology, 23(12), 1788–1798. https://doi.org/10.1038/s41590-022-01328-6